The C-Scan test is a capsule-based screening technology used to detect polyps before they turn into cancer. The test uses an ultralow-dose X-ray capsule and a proprietary software system to generate a map of the inner lining of the colon as it travels through the gastrointestinal tract. The test requires no bowel preparation and is noninvasive. The test, however, is not a colonoscopy replacement and all positive C-Scan tests should be followed by a colonoscopy.
Check-Cap will soon launch a U.S.-based trial late this year to evaluate test performance in average-risk individuals.
Alex Ovadia, CEO of Check-Cap, said, “We believe that this highlights the FDA’s recognition of C-Scan as an alternative method to address the significant unmet need for patient-friendly CRC screening, in particular since it enables the detection of CRC polyps before they may turn into cancer.”
News of the approval boosted the company’s stock price from around $1.50 to $4.04 at market open March 15.
More articles on physicians:
2 private ENT practices merge in South Dakota
Is the future bright or dark for independent ASCs?
Dr. Jeffrey Carlson performs 3-level lumbar fusion at Virginia ASC
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
